Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome

BMC Gastroenterology

Mark S Riddle⁴  Akintunde Akinseye²  Mark Pimentel³  Brooks D Cash¹  Chad K Porter⁴ 

[1] National Naval Medical Center, Gastroenterology, Bethesda, MD, USA;George Washington University, School of Public Health and Health Services, School of Medicine and Health Sciences, Washington, DC, USA;Cedars-Sinai Medical Center, Los Angeles, Gastrointestinal Motility Program and Laboratory, Los Angeles, CA, USA;Enteric Diseases Department, Infectious Disease Directorate, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD, USA

关键词: Ulcerative colitis;    Crohn’s disease;    Infectious gastroenteritis;    Irritable bowel syndrome;    Inflammatory bowel disease;   

Others  :  1113062
DOI  :  10.1186/1471-230X-12-55

 received in 2011-08-29, accepted in 2012-04-24,  发布年份 2012

【 摘 要 】

Background

Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) symptoms often overlap. In some IBS cases there are subtle inflammatory changes similar to the immune-mediated pathophysiology of IBD, and the risk of both increases after infectious gastroenteritis (IGE).

Methods

To evaluate the effect of IBS and IGE on IBD risk utilizing US Department of Defense medical encounter data, active duty personnel with IBS were matched to subjects without IBS. Medical encounter history was analyzed to assess for incident IBD. IGE was identified from documented medical encounters and by self-report. Relative risks were calculated using Poisson regression models.

Results

We identified 9,341 incident IBS cases and 18,678 matched non-IBS subjects and found an 8.6-fold higher incidence (p < 0.0001) of IBD among those with IBS (238.1 per 100,000 person-years) compared to our referent population (27.8 per 100,000 person-years). In a subset (n = 2,205) of well-defined IBS cases, IBD risk was 15 times that of subjects without IBS. The median time between IBS and IBD diagnoses was 2.1 years. IGE also increased IBD risk approximately 2-fold ( p < 0.05) after controlling for IBS.

Conclusions

These data reflect a complex interaction between illness presentation and diagnosis of IBS and IBD and suggest intercurrent IGE may increase IBD risk in IBS patients. Additional studies are needed to determine whether IBS lies on the causal pathway for IBD or whether the two are on a pathophysiological spectrum of the same clinical illness. These data suggest consideration of risk reduction interventions for IGE among IBS patients at high disease risk.

【 授权许可】

   
2012 Porter et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Cash B, Sullivan S, Barghout V: Total costs of IBS: employer and managed care perspective. Am J Manag Care 2005, 11:S7-S16.
• [2]Horwitz BJ, Fisher RS: The irritable bowel syndrome. N Engl J Med 2001, 344:1846-1850.
• [3]Levy RL, Von Korff M, Whitehead WE, Stang P, Saunders K, Jhingran P, Barghout V, Feld AD: Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001, 96:3122-3129.
• [4]Bercik P, Verdu EF, Collins SM: Is irritable bowel syndrome a low-grade inflammatory bowel disease. Gastroenterol Clin North Am 2005, 34:235-245. vi-vii
• [5]Garcia Rodriguez LA, Ruigomez A, Wallander MA, Johansson S, Olbe L: Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. Scand J Gastroenterol 2000, 35:306-311.
• [6]Porter CK, Tribble DR, Aliaga PA, Halvorson HA, Riddle MS: Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology 2008, 135:781-786.
• [7]Pimentel M, Chang M, Chow EJ, Tabibzadeh S, Kirit-Kiriak V, Targan SR, Lin HC: Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Am J Gastroenterol 2000, 95:3458-3462.
• [8]Ginsburg PM, Bayless TM: How can IBD be distinguished from IBS? Inflamm Bowel Dis 2008, 14(Suppl 2):S152-S154.
• [9]Gradel KO, Nielsen HL, Schonheyder HC, Ejlertsen T, Kristensen B, Nielsen H: Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology 2009, 137:495-501.
• [10]Ternhag A, Torner A, Svensson A, Ekdahl K, Giesecke J: Short- and long-term effects of bacterial gastrointestinal infections. Emerg Infect Dis 2008, 14:143-148.
• [11]Halvorson HA, Schlett CD, Riddle MS: Postinfectious irritable bowel syndrome--a meta-analysis. Am J Gastroenterol 2006, 101:1894-1899. quiz 1942
• [12]Thabane M, Kottachchi DT, Marshall JK: Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007, 26:535-544.
• [13]Quigley EM: Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases? Chin J Dig Dis 2005, 6:122-132.
• [14]Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC: Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006, 101:1288-1294.
• [15]Porter CK, Gormley R, Tribble DR, Cash BD, Riddle MS: The Incidence and Gastrointestinal Infectious Risk of Functional Gastrointestinal Disorders in a Healthy US Adult Population. Am J Gastroenterol 2011, 106:130-138.
• [16]Garcia Rodriguez LA, Ruigomez A, Panes J: Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 2006, 130:1588-1594.
• [17]Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM: Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006, 131:445-450. quiz 660
• [18]Chen ML, Ge Z, Fox JG, Schauer DB: Disruption of tight junctions and induction of proinflammatory cytokine responses in colonic epithelial cells by Campylobacter jejuni. Infect Immun 2006, 74:6581-6589.
• [19]Kalischuk LD, Buret AG: A role for Campylobacter jejuni-induced enteritis in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2010, 298:G1-G9.
• [20]Kalischuk LD, Inglis GD, Buret AG: Campylobacter jejuni induces transcellular translocation of commensal bacteria via lipid rafts. Gut Pathog 2009, 1:2. BioMed Central Full Text
• [21]Villani AC, Lemire M, Thabane M, Belisle A, Geneau G, Garg AX, Clark WF, Moayyedi P, Collins SM, Franchimont D, Marshall JK: Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010, 138:1502-1513.
• [22]Schneider MR, Dahlhoff M, Horst D, Hirschi B, Trulzsch K, Muller-Hocker J, Vogelmann R, Allgauer M, Gerhard M, Steininger S, Wolf E, Kolligs FT: A key role for E-cadherin in intestinal homeostasis and Paneth cell maturation. PLoS One 2010, 5:e14325.
• [23]van Sommeren S, Visschedijk MC, Festen EA, de Jong DJ, Ponsioen CY, Wijmenga C, Weersma RK: HNF4alpha and CDH1 are associated with ulcerative colitis in a Dutch cohort. Inflamm Bowel Dis 2011, 17:1714-1718.
• [24]Chae SC, Yu JI, Oh GJ, Choi CS, Choi SC, Yang YS, Yun KJ: Identification of single nucleotide polymorphisms in the TNFRSF17 gene and their association with gastrointestinal disorders. Mol Cells 2010, 29:21-28.
• [25]Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, Moses PL: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004, 126:1657-1664.
• [26]Spiegel BM, Farid M, Esrailian E, Talley J, Chang L: Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010, 105:848-858.
• [27]Yantiss RK, Odze RD: Diagnostic difficulties in inflammatory bowel disease pathology. Histopathology 2006, 48:116-132.
• [28]Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J: Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996–2002. Am J Gastroenterol 2008, 103:1998-2006.
• [29]Locke GR, Yawn BP, Wollan PC, Melton LJ, Lydick E, Talley NJ: Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population. Aliment Pharmacol Ther 2004, 19:1025-1031.
• [30]Curry JA, Riddle MS, Gormley RP, Tribble DR, Porter CK: The epidemiology of infectious gastroenteritis related reactive arthritis in U.S. military personnel: a case–control study. BMC Infect Dis 2010, 10:266. BioMed Central Full Text
• [31]DuPont HL, Galler G, Garcia-Torres F, Dupont AW, Greisinger A, Jiang ZD: Travel and travelers' diarrhea in patients with irritable bowel syndrome. AmJTrop Med Hyg 2010, 82:301-305.
• [32]Scallan E, Jones TF, Cronquist A, Thomas S, Frenzen P, Hoefer D, Medus C, Angulo FJ: Factors associated with seeking medical care and submitting a stool sample in estimating the burden of foodborne illness. Foodborne Pathog Dis 2006, 3:432-438.
• [33]Macsharry J, O'Mahony L, Fanning A, Bairead E, Sherlock G, Tiesman J, Fulmer A, Kiely B, Dinan TG, Shanahan F, Quigley EM: Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008, 43:1467-1476.
• [34]Cabada MM, White AC: Travelers' diarrhea: an update on susceptibility, prevention, and treatment. Curr Gastroenterol Rep 2008, 10:473-479.
• [35]Sekirov I, Finlay BB: The role of the intestinal microbiota in enteric infection. J Physiol 2009, 587:4159-4167.
• [36]Barbara G: Mucosal barrier defects in irritable bowel syndrome. Who left the door open? Am J Gastroenterol 2006, 101:1295-1298.
• [37]Gecse K, Roka R, Ferrier L, Leveque M, Eutamene H, Cartier C, Ait-Belgnaoui A, Rosztoczy A, Izbeki F, Fioramonti J, Wittmann T, Bueno L: Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008, 57:591-599.
• [38]Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche JP, Neunlist M: Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009, 58:196-201.
• [39]DuPont HL: Systematic review: the epidemiology and clinical features of travellers' diarrhoea. Aliment Pharmacol Ther 2009, 30:187-196.
• [40]Riddle MS, Sanders JW, Putnam SD, Tribble DR: Incidence, etiology, and impact of diarrhea among long-term travelers (U.S. military and similar populations): A systematic review. AmJTrop Med Hyg 2006, 74:891-900.
• [41]Travelers' diarrhea: National Institutes of Health Consensus Development Conference Rev Infect Dis 1986, 8(Suppl 2):S109-S233. Bethesda, Maryland, January 28–30, 1985
• [42]Hill DR, Ericsson CD, Pearson RD, Keystone JS, Freedman DO, Kozarsky PE, DuPont HL, Bia FJ, Fischer PR, Ryan ET: The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006, 43:1499-1539.
• [43]Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A: Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999, 149:916-924.